Srikar Chem & Pharma India Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
- Paid Up Capital ₹ 1.46 Cr
- Company Age 14 Year, 7 Days
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 66.44%
- Profit Growth 211.34%
- Ebitda 453.63%
- Net Worth 268.70%
- Total Assets 29.64%
About Srikar Chem & Pharma India
Srikar Chem & Pharma India Private Limited (SCPIPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 01 February 2011 and has a history of 14 years. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 1.46 Cr, as per Ministry of Corporate Affairs (MCA) records.
Narravula Anuradha and Geyana Narravula serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24100TG2011PTC072439
-
Company No.
072439
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
01 Feb 2011
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Srikar Chem & Pharma India?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narravula Anuradha
|
Director | 20-Nov-2019 | Current |
|
Geyana Narravula
|
Director | 20-Nov-2019 | Current |
Financial Performance of Srikar Chem & Pharma India.
Srikar Chem & Pharma India Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 66.44% increase. The company also saw a substantial improvement in profitability, with a 211.34% increase in profit. The company's net worth Soared by an impressive increase of 268.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Srikar Chem & Pharma India?
In 2019, Srikar Chem & Pharma India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Srikar Chem & Pharma India?
Srikar Chem & Pharma India has a workforce of 28 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Srikar Chem & Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Srikar Chem & Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
